News ViiV's Cabenuva enhances control of unsuppressed HIV ViiV's long-acting injectable HIV drug, Cabenuva, has proved to be more effective than daily oral therapy for unsuppressed infections.
News NICE says no to Gilead's lenacapavir for HIV PrEP NICE's decision not to recommend NHS funding of Gilead's twice-yearly injectable for prevention of HIV has drawn fierce criticism from charities.
News ViiV wins US approval for HIV treatment in newborn babies The US FDA has green lit ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in children weighing at least 2 kg.
News OpenAI Foundation pledges $100m to boost hepatitis C cure ra... The OpenAI Foundation has committed $100m to help fund a new public health initiative initially focused on hepatitis C.
News HIV resurgence looming as international aid declines More than 3m people worldwide could be infected with HIV by the end of the decade following a steep fall in international aid funding, says UNAIDS.
News Gilead, MSD share data on once-weekly oral HIV treatment Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.